Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Roche and BioLamina Start Collaboration to Develop Novel Cell Culture Systems

Published: Wednesday, March 06, 2013
Last Updated: Wednesday, March 06, 2013
Bookmark and Share
Research focus on investigation of laminin-based approaches.

Roche and BioLamina, Stockholm, Sweden today announced the signing of a research and development agreement to jointly develop new cell culture systems for various applications, including stem cell research. The collaboration will focus on assessing laminin-based in-vitro cell culture matrices offering highly physiological microenvironments for living cells. Under the terms of the agreement Roche will provide R&D funding and scientific expertise to BioLamina. Financial details were not disclosed.

Laminins are proteins located in the extracellular matrix providing the stability essential for cell growth and behaviour. They are the only protein group in this environment that have a tissue-specific distribution, including expression of specific laminins during embryonic development. This makes them a very interesting target for new biologically relevant cell culturing techniques.

“Our aim is to develop laminin-based culture systems that provide biologically relevant, standardized environments”, said Ruedi Stoffel, Head of Biochemical Reagents & Custom Biotech at Roche. “We are looking forward to this collaboration to build on the revolutionary cell cultivation techniques developed by our colleagues at the Karolinska Institute and BioLamina.”

“We’re delighted that Roche has recognized the potential of our products and technology, which we believe will significantly complement their expertise and capabilities in cell culturing,” states Kristian Tryggvason, CEO of BioLamina. “By resolving many of the technical obstacles currently blocking the road to modern cell therapy, we expect this collaboration to accelerate the development of innovative cell culturing solutions that possibly can enable cell therapy”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche’s MabThera SC Receives Approval in Europe
Company has announced that the EC has approved the SC formulation of MabThera® for people with previously untreated chronic lymphocytic leukaemia (CLL).
Friday, June 03, 2016
FDA Grants Roche’s Cancer Immunotherapy Tecentriq Accelerated Approval
Company has announced that the U.S. FDA has granted accelerated approval to Tecentriq® for the treatment of people with a specific type of advanced bladder cancer.
Friday, May 20, 2016
Blueprint Medicine, Roche Collaborate
Collaboration combines blueprint medicines' proprietary drug discovery platform and immunokinase expertise with Roche's cancer immunotherapy expertise.
Wednesday, March 16, 2016
Tensha Therapeutics to be Acquired by Roche
Tensha Therapeutics, a privately-held company based in Cambridge, MA, has announced it will be acquired by Roche.
Tuesday, January 12, 2016
Roche to Restructure its Manufacturing Network for Small Molecules
Changes to address shift to new generation of medicines.
Tuesday, November 24, 2015
Roche Receives FDA Approval for Viral Load Tests and Cobas 6800/8800 Systems
Roche has received FDA approval for the cobas® HBV and cobas® HCV viral load tests, the first assays approved by the FDA for use on the cobas® 6800 and cobas® 8800 Systems.
Sunday, October 18, 2015
Roche Launches the cobas EGFR Mutation Test v2
New test is the first to be validated for use of either sample type in a single test.
Wednesday, October 14, 2015
Roche Introduces Enhanced Whole Exome Sequencing Solution
The company has announced the launch of the SeqCap EZ MedExome Target Enrichment Kit1.
Wednesday, September 23, 2015
US FDA Grants Therapy Designation for Roche’s Investigational Medicine ACE910
First factor VIIIa-mimetic bispecific antibody to be investigated for the prophylactic treatment of haemophilia A.
Tuesday, September 08, 2015
Roche to Acquire Kapa Biosystems
Acquisition to strengthen next-generation sequencing product offerings.
Friday, August 21, 2015
Roche's Investigational Immunotherapy Atezolizumab Shrank Tumours in People with Lung Cancer
Roche will discuss results with the U.S. FDA as part of atezolizumab’s Breakthrough Therapy Designation in lung cancer.
Wednesday, August 19, 2015
Pivotal Phase II Study of Venetoclax Met Primary Endpoint
Venetoclax is a small molecule inhibitor of the BCL-2 protein, which potentially represents a new way of treating blood cancers.
Friday, August 14, 2015
Roche Acquires GeneWEAVE to Strengthen Offerings in Microbiology Diagnostics
GeneWEAVE’s Smarticles technology enhances Roche’s role in fighting drug-resistant bacteria.
Friday, August 14, 2015
Roche's Investigational Immunotherapy Shrank Bladder Cancer Tumors in Pivotal Study
The company have announced the success of atezolizumab in shrinking tumors people with locally advanced or metastatic urothelial bladder cancer.
Tuesday, July 14, 2015
Roche Acquires Ariosa Diagnostics
Acquisition will see Roche enter the non-invasive prenatal test (NIPT) and cell-free DNA testing services markets.
Wednesday, December 03, 2014
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Four Newly-Identified Genes Could Improve Rice
A Japanese research team have applied a method used in human genetic analysis to rice and rapidly discovered four new genes that are potentially significant for agriculture. These findings could influence crop breeding and help combat food shortages caused by a growing population.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Antibodies To Dengue May Alter Course Of Zika Virus Infection
Scientists at Emory Vaccine Center, in collaboration with investigators from Thailand, have found that people infected with dengue virus develop antibodies that cross-react with Zika virus.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!